Viatris said the Board increased the number of directors on the Board from 11 to 12 on June 3, 2024 and appointed Rogério Vivaldi Coelho, M.D., M.B.A., as an independent director under NASDAQ listing rules.

1. 01

   Viatris said the Board increased the number of directors on the Board from 11 to 12 on June 3, 2024 and appointed Rogério Vivaldi Coelho, M.D., M.B.A., as an independent director under NASDAQ listing rules.

2. 02

   The company said Dr. Vivaldi's term expires at the 2024 annual shareholder meeting and that he was assigned to the recently reestablished Science and Technology Committee. It said both appointments took effect on June 3, 2024.

3. 03

   The company said Dr. Vivaldi will receive compensation consistent with that of the company's other non-employee directors and has entered into an indemnification agreement with him. It said there are no arrangements or understandings under which he was selected as a director and that he has no material interest requiring disclosure under Item 404(a).

4. 04

   In a press release, Viatris described Dr. Vivaldi as the former President and Chief Executive Officer of Sigilon Therapeutics. It said he led the approval of more than 20 orphan products in more than 15 countries during his tenure at Genzyme.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.